戻る Agenda
[V5-S3] Approaches to Enhance Appropriate Communication on Pharmaceutical Product Information
Session Chair(s)
Mamoru Narukawa, PhD, RPh
Professor
Kitasato University, Japan
Yuko Kojima, RPh
Sr. Executive Director
Eli Lilly Japan K.K., Japan
It is highly important that pharmaceutical product information is appropriately provided by regulatory authorities and pharmaceutical companies, and utilized in the medical field. In the Japan annual meeting in 2016, we discussed issues arising from provision of pharmaceutical product information materials provided to healthcare professionals or patients, and handling of these issues. We have found that pharmaceutical product information is not necessarily fully utilized by the medical professionals: duplicate information is provided using various materials from the regulatory authorities and companies, necessary information for medical professionals is not provided, and the real intentions of the authors are not fully conveyed. In 2017, we will discuss approaches and future perspectives to enhance appropriate communication on pharmaceutical product information to medical professionals based on the previous discussion by summarizing the objectives and utilization methods of a wide range of information materials provided by the regulatory authorities and companies.
Speaker(s)
Tomoko Tanita
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Risk Communication Promotion Division, Office of Safety I
Susumu Wakabayashi
Kyorin University Hospital, Japan
Department of Pharmacy
Shinya Takemoto, MSc
Chugai Pharmaceutical Co., Ltd., Japan
Group Manager, Safety Information Strategy Group, Risk Communication Department
Junichi Nishino, MSc, RPh
Otsuka Pharmaceutical Co., Ltd., Japan
Head, Regulatory Affairs Department
Toyotaka Iguchi, MD, PhD
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Director, Office of Safety II